Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 2/2022

15.09.2021 | COVID-19 Zur Zeit gratis

Prophylactic versus therapeutic anticoagulation for survival of patients with COVID-19 on steroid

verfasst von: Toshiki Kuno, Matsuo So, Mai Takahashi, Natalia N. Egorova

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Previous observational and randomized studies suggested potential benefit of therapeutic anticoagulation during hospitalization, but this treatment remains controversial. As of June 30th 2021, steroids is the standard treatment of COVID patients. We aimed to investigate the association of prophylactic and therapeutic anticoagulation with mortality for patients with COVID-19 who were treated with steroids. We retrospectively reviewed the medical records of 2533 patients discharged between March 1st, 2020 and March 30th, 2021, with laboratory-confirmed COVID-19 in the Mount Sinai Health System and treated with steroids. We evaluated the effect of therapeutic versus prophylactic anticoagulation on the outcomes using propensity score analyses. Subgroup analyses were conducted by stratification of patients by endotracheal intubation. Among the 2533 eligible patients, 465 (18.4%) received therapeutic anticoagulation. After 1:1 propensity score matching (N = 383 pairs), in-hospital mortality was similar between those with therapeutic versus prophylactic anticoagulation (36.0% versus 30.0%, P = 0.091). In-hospital mortality regardless of endotracheal intubation were not significantly different between the two groups. Therapeutic anticoagulation was not associated with reduced or increased risk of in-hospital mortality in patients with COVID-19 treated with steroids.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Nadkarni GN, Lala A, Bagiella E, Chang HL, Moreno PR, Pujadas E et al (2020) Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. J Am Coll Cardiol 76(16):1815–1826CrossRef Nadkarni GN, Lala A, Bagiella E, Chang HL, Moreno PR, Pujadas E et al (2020) Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. J Am Coll Cardiol 76(16):1815–1826CrossRef
3.
Zurück zum Zitat Group WHOREAfC-TW, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J et al (2020) Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 324(13):1330–41CrossRef Group WHOREAfC-TW, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J et al (2020) Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 324(13):1330–41CrossRef
5.
Zurück zum Zitat Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y et al (2020) Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 369:m1966CrossRef Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y et al (2020) Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 369:m1966CrossRef
6.
Zurück zum Zitat Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin MA et al (2020) Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol 76(1):122–124CrossRef Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin MA et al (2020) Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol 76(1):122–124CrossRef
10.
Zurück zum Zitat Takahashi M, Egorova NN, Kuno T (2021) COVID-19 and influenza testing in New York City. J Med Virol 93(2):698–701CrossRef Takahashi M, Egorova NN, Kuno T (2021) COVID-19 and influenza testing in New York City. J Med Virol 93(2):698–701CrossRef
11.
Zurück zum Zitat Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O et al (2017) Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377(14):1319–1330CrossRef Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O et al (2017) Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377(14):1319–1330CrossRef
12.
Zurück zum Zitat Chandiramani R, Cao D, Nicolas J, Mehran R (2020) Contrast-induced acute kidney injury. Cardiovasc Interv Ther 35(3):209–217CrossRef Chandiramani R, Cao D, Nicolas J, Mehran R (2020) Contrast-induced acute kidney injury. Cardiovasc Interv Ther 35(3):209–217CrossRef
13.
Zurück zum Zitat Austin PC (2009) The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Mak 29(6):661–677CrossRef Austin PC (2009) The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Mak 29(6):661–677CrossRef
14.
Zurück zum Zitat Yokoyama Y, Briasoulis A, Takagi H, Kuno T (2020) Effect of remdesivir on patients with COVID-19: a network meta-analysis of randomized control trials. Virus Res 288:198137CrossRef Yokoyama Y, Briasoulis A, Takagi H, Kuno T (2020) Effect of remdesivir on patients with COVID-19: a network meta-analysis of randomized control trials. Virus Res 288:198137CrossRef
16.
Zurück zum Zitat Acosta-Ochoa I, Bustamante-Munguira J, Mendiluce-Herrero A, Bustamante-Bustamante J, Coca-Rojo A (2019) Impact on outcomes across KDIGO-2012 AKI criteria according to baseline renal function. J Clin Med 8(9):1323CrossRef Acosta-Ochoa I, Bustamante-Munguira J, Mendiluce-Herrero A, Bustamante-Bustamante J, Coca-Rojo A (2019) Impact on outcomes across KDIGO-2012 AKI criteria according to baseline renal function. J Clin Med 8(9):1323CrossRef
17.
Zurück zum Zitat Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS (2020) Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med 8(7):681–686CrossRef Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS (2020) Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med 8(7):681–686CrossRef
18.
Zurück zum Zitat Yamakawa M, Kuno T, Mikami T, Takagi H, Gronseth G (2020) Clinical characteristics of stroke with COVID-19: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis 29(12):105288CrossRef Yamakawa M, Kuno T, Mikami T, Takagi H, Gronseth G (2020) Clinical characteristics of stroke with COVID-19: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis 29(12):105288CrossRef
19.
Zurück zum Zitat Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W et al (2020) Coagulopathy and antiphospholipid antibodies in patients with covid-19. N Engl J Med 382(17):e38CrossRef Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W et al (2020) Coagulopathy and antiphospholipid antibodies in patients with covid-19. N Engl J Med 382(17):e38CrossRef
20.
Zurück zum Zitat Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E et al (2020) COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol 75(23):2950–2973CrossRef Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E et al (2020) COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol 75(23):2950–2973CrossRef
21.
Zurück zum Zitat Zhang L, Feng X, Zhang D, Jiang C, Mei H, Wang J et al (2020) Deep vein thrombosis in hospitalized patients with COVID-19 in Wuhan, China: prevalence, risk factors, and outcome. Circulation 142(2):114–128CrossRef Zhang L, Feng X, Zhang D, Jiang C, Mei H, Wang J et al (2020) Deep vein thrombosis in hospitalized patients with COVID-19 in Wuhan, China: prevalence, risk factors, and outcome. Circulation 142(2):114–128CrossRef
22.
Zurück zum Zitat Marginean A, Masic D, Brailovsky Y, Fareed J, Darki A (2020) Difficulties of managing submassive and massive pulmonary embolism in the era of COVID-19. JACC Case Rep 2(9):1383–1387CrossRef Marginean A, Masic D, Brailovsky Y, Fareed J, Darki A (2020) Difficulties of managing submassive and massive pulmonary embolism in the era of COVID-19. JACC Case Rep 2(9):1383–1387CrossRef
23.
Zurück zum Zitat Spyropoulos AC, Weitz JI (2020) Hospitalized COVID-19 patients and venous thromboembolism: a perfect storm. Circulation 142(2):129–132CrossRef Spyropoulos AC, Weitz JI (2020) Hospitalized COVID-19 patients and venous thromboembolism: a perfect storm. Circulation 142(2):129–132CrossRef
24.
Zurück zum Zitat Piazza G, Campia U, Hurwitz S, Snyder JE, Rizzo SM, Pfeferman MB et al (2020) Registry of arterial and venous thromboembolic complications in patients with COVID-19. J Am Coll Cardiol 76(18):2060–2072CrossRef Piazza G, Campia U, Hurwitz S, Snyder JE, Rizzo SM, Pfeferman MB et al (2020) Registry of arterial and venous thromboembolic complications in patients with COVID-19. J Am Coll Cardiol 76(18):2060–2072CrossRef
25.
Zurück zum Zitat Konstantinides SV (2020) Thrombosis and thromboembolism related to COVID-19: increase the level of awareness, lower the threshold of suspicion, and keep following the guidelines. JACC Case Rep 2(9):1388–1390CrossRef Konstantinides SV (2020) Thrombosis and thromboembolism related to COVID-19: increase the level of awareness, lower the threshold of suspicion, and keep following the guidelines. JACC Case Rep 2(9):1388–1390CrossRef
26.
Zurück zum Zitat Tritschler T, Mathieu ME, Skeith L, Rodger M, Middeldorp S, Brighton T et al (2020) Anticoagulant interventions in hospitalized patients with COVID-19: a scoping review of randomized controlled trials and call for international collaboration. J Thromb Haemost 18:2958CrossRef Tritschler T, Mathieu ME, Skeith L, Rodger M, Middeldorp S, Brighton T et al (2020) Anticoagulant interventions in hospitalized patients with COVID-19: a scoping review of randomized controlled trials and call for international collaboration. J Thromb Haemost 18:2958CrossRef
27.
Zurück zum Zitat Houston BL, Lawler PR, Goligher EC, Farkouh ME, Bradbury C, Carrier M et al (2020) Anti-thrombotic therapy to ameliorate complications of COVID-19 (ATTACC): study design and methodology for an international, adaptive Bayesian randomized controlled trial. Clin Trials 17(5):491–500CrossRef Houston BL, Lawler PR, Goligher EC, Farkouh ME, Bradbury C, Carrier M et al (2020) Anti-thrombotic therapy to ameliorate complications of COVID-19 (ATTACC): study design and methodology for an international, adaptive Bayesian randomized controlled trial. Clin Trials 17(5):491–500CrossRef
28.
Zurück zum Zitat Marietta M, Vandelli P, Mighali P, Vicini R, Coluccio V, D’Amico R et al (2020) Randomised controlled trial comparing efficacy and safety of high versus low low-molecular weight heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol. Trials 21(1):574CrossRef Marietta M, Vandelli P, Mighali P, Vicini R, Coluccio V, D’Amico R et al (2020) Randomised controlled trial comparing efficacy and safety of high versus low low-molecular weight heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol. Trials 21(1):574CrossRef
31.
Zurück zum Zitat Investigators R-C, Investigators AC-a, Investigators A, Goligher EC, Bradbury CA, McVerry BJ et al (2021) Therapeutic anticoagulation with heparin in critically ill patients with covid-19. N Engl J Med 385(9):777–89CrossRef Investigators R-C, Investigators AC-a, Investigators A, Goligher EC, Bradbury CA, McVerry BJ et al (2021) Therapeutic anticoagulation with heparin in critically ill patients with covid-19. N Engl J Med 385(9):777–89CrossRef
32.
Zurück zum Zitat Investigators A, Investigators AC-a, Investigators R-C, Lawler PR, Goligher EC, Berger JS et al (2021) Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19. N Engl J Med 385(9):790–802CrossRef Investigators A, Investigators AC-a, Investigators R-C, Lawler PR, Goligher EC, Berger JS et al (2021) Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19. N Engl J Med 385(9):790–802CrossRef
Metadaten
Titel
Prophylactic versus therapeutic anticoagulation for survival of patients with COVID-19 on steroid
verfasst von
Toshiki Kuno
Matsuo So
Mai Takahashi
Natalia N. Egorova
Publikationsdatum
15.09.2021
Verlag
Springer US
Schlagwort
COVID-19
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 2/2022
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-021-02569-2

Weitere Artikel der Ausgabe 2/2022

Journal of Thrombosis and Thrombolysis 2/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.